Histamine and spontaneous motor activity: Biphasic changes, receptors involved and participation of the striatal dopamine system

doi:10.1016/S0024-3205(98)00154-4

Life Sciences

Volume 62, Issue 20, 10 April 1998, Pages 1875-1888

https://doi.org/10.1016/S0024-3205(98)00154-4 Get rights and content

Abstract

The time- and dose-related effects of exogenous histamine on spontaneous motor activity and receptors involved were evaluated in male rats. Intracerebroventricular administration of histamine (5.4 and 54.3 nmol) produced a biphasic effect with initial transitory hypoactivity and later hyperactivity expressed by locomotion frequency in an open-field. The rearing frequencies were only reduced by all doses of histamine used. The histamine-induced hypoactivity was inhibited by the H₃-antagonist thioperamide and was also induced by the H₃-agonist N-α-methylhistamine. The histamine-induced hyperactivity phase was blocked by the H₁-antagonist mepyramine. The H₂-antagonist ranitidine increased locomotion and rearing frequencies. The participation of other neurotransmitters in the persistent hypokinetic effect induced by 135.8 nmol of histamine was determined by HPLC in the striatum and hypothalamus as counter-proof. A decreased DOPAC/DA ratio was observed only in the striatum. In the hypothalamus, low levels of 5HT were detected, probably not correlated with motor activiry. In conclusion, the present results suggest that the exogenous histamine-induced hypoactivity response is probably due to activation of H₃-receptors as heteroreceptors reducing the activity of the striatal dopaminergic system. This effect can partially overlap with the expression of the hyperactivity induced by H₁-receptor activation. The participation of H₂-receptors requires further investigation.

References (48)

K. Onodera et al.
Progr. Neurobiol.
(1994)
C.R. Calcutt et al.
Neurosci. Lett.
(1976)
E.O. Alvarez et al.
Physiol. Behav.
(1985)
E.O. Alvarez et al.
Physiol. Behav.
(1986)
E.O. Alvarez et al.
Physiol. Behav.
(1982)
J.M. Arrang et al.
Neuroscience
(1985)
J.M. Arrang et al.
Neuroscience
(1987)
N. Sakai et al.
Life Sci.
(1991)
M. Imaizumi et al.
Life Sci.
(1993)
E.O. Alvarez et al.
Behav. Brain Res.
(1992)

T. Suzuki et al.

Brain Res.

(1995)

J.-S. Lin et al.

Brain Res.

(1990)

J. Clapham et al.

Eur. J. Pharmacol.

(1994)

R.J. Beninger

Brain Res. Rev.

(1983)

J.Z. Nowak et al.

Eur. J. Pharmacol.

(1977)

N. Subramanian et al.

Eur. J. Pharmacol.

(1977)

A.E. Fleckenstein et al.

Eur. J. Pharmacol.

(1994)

A. Pilc et al.

Eur. J. Pharmacol.

(1979)

J.-C. Schwartz et al.

Physiol. Rev.

(1991)

P.W. Kalivas

J. Pharmacol. Exp. Ther.

(1982)

G. Nistico et al.

Res. Commun. Chem. Pathol. Pharmacol.

(1980)

L. Tuomisto et al.

Agents Actions

(1980)

J.P. Hanig et al.

Arch. Int. Pharmacodyn. Ther.

(1973)

K. Onodera et al.

Cited by (53)

Maternal allergic inflammation in rats impacts the offspring perinatal neuroimmune milieu and the development of social play, locomotor behavior, and cognitive flexibility
2021, Brain, Behavior, and Immunity
Maternal systemic inflammation increases risk for neurodevelopmental disorders like autism, ADHD, and schizophrenia in offspring. Notably, these disorders are male-biased. Studies have implicated immune system dysfunction in the etiology of these disorders, and rodent models of maternal immune activation provide useful tools to examine mechanisms of sex-dependent effects on brain development, immunity, and behavior. Here, we employed an allergen-induced model of maternal inflammation in rats to characterize levels of mast cells and microglia in the perinatal period in male and female offspring, as well as social, emotional, and cognitive behaviors throughout the lifespan. Adult female rats were sensitized to ovalbumin (OVA), bred, and challenged intranasally on gestational day 15 of pregnancy with OVA or saline. Allergic inflammation upregulated microglia in the fetal brain, increased mast cell number in the hippocampus on the day of birth, and conferred region-, time- and sex- specific changes in microglia measures. Additionally, offspring of OVA-exposed mothers subsequently exhibited abnormal social behavior, hyperlocomotion, and reduced cognitive flexibility. These data demonstrate the long-term effects of maternal allergic challenge on offspring development and provide a basis for understanding neurodevelopmental disorders linked to maternal systemic inflammation in humans.
Reduced locomotor activity and exploratory behavior in CC chemokine receptor 4 deficient mice
2016, Behavioural Brain Research
Chemokines and their receptors are key regulators of immune cell trafficking and activation. Recent findings suggest that they may also play pathophysiological roles in psychiatric diseases like depression and anxiety disorders. The CC chemokine receptor 4 (CCR4) and its two ligands, CCL17 and CCL22, are functionally involved in neuroinflammation as well as anti-infectious and autoimmune responses. However, their influence on behavior remains unknown. Here we characterized the functional role of the CCR4-CCL17 chemokine-receptor axis in the modulation of anxiety-related behavior, locomotor activity, and object exploration and recognition. Additionally, we investigated social exploration of CCR4 and CCL17 knockout mice and wild type (WT) controls. CCR4 knockout (CCR4^−/−) mice exhibited fewer anxiety-related behaviors in the elevated plus-maze, diminished locomotor activity, exploratory behavior, and social exploration, while their recognition memory was not affected. In contrast, CCL17 deficient mice did not show an altered behavior compared to WT mice regarding locomotor activity, anxiety-related behavior, social exploration, and object recognition memory. In the dark-light and object recognition tests, CCL17^−/− mice even covered longer distances than WT mice. These data demonstrate a mechanistic or developmental role of CCR4 in the regulation of locomotor and exploratory behaviors, whereas the ligand CCL17 appears not to be involved in the behaviors measured here. Thus, either CCL17 and the alternative ligand CCL22 may be redundant, or CCL22 is the main activator of CCR4 in these processes. Taken together, these findings contribute to the growing evidence regarding the involvement of chemokines and their receptors in the regulation of behavior.
Contribution of the central histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol
2015, Pharmacology Biochemistry and Behavior
Citation Excerpt :
Considering all the points, our observation on the influence of H2 receptor antagonist on haloperidol-induced behavioral effects seem to be promising, as the role of H2 receptor in the modulation of central dopaminergic activity, especially in basal ganglia has been already suggested. Few researchers demonstrated lack of effect of H2 receptor on dopaminergic activity (Chiavegatto et al., 1998) while some demonstrated both increased (Farzin and Attarzadeh, 2000; Liu et al., 2007; Otsuka et al., 2003) and reduced (Hamami et al., 2004) dopamine activity in the CNS after H2 receptor stimulation or antagonism. However, our experimental outcome clearly points towards a possible anti-dopaminergic like activity of histamine via H1 or H2 receptor stimulation that might be responsible for the observed potentiating effects of l-histidine on haloperidol-induced cataleptic and neuroleptic effects.
The antipsychotic properties of haloperidol are primarily attributed to its ability to block dopamine D₂ receptors. Histaminergic transmission modulates some of the behavioral effects of haloperidol. Hence, the present study investigated the contribution of central histaminergic transmission in the cataleptic and neuroleptic effect of haloperidol respectively, using bar test and conditioned avoidance response (CAR) in a two-way shuttle box. The studies revealed that haloperidol (0.50 or 1 mg/kg, i.p.) exhibited cataleptic behavior and inhibited conditioned avoidance response (CAR) in the doses 0.25 or 0.50 mg in rats. The rats, pretreated centrally (i.c.v.) with histamine precursor, l-histidine (1, 2.5 μg) or histamine neuronal inducer (H₃ receptor antagonist), thioperamide (20, 50 μg/rat), showed an enhanced cataleptic effect with sub-maximal dose of haloperidol (0.5 mg/kg, i.p.). Similarly, the neuroleptic effect of haloperidol (0.25 mg/kg, i.p.) in CAR was also potentiated in the rats pretreated with l-histidine (2.5 μg) or thioperamide (50 μg/rat). Further, the cataleptic effect of haloperidol (1 mg/kg, i.p.) was attenuated in rats pretreated with the H₁ receptor antagonist, chlorpheniramine (60, 80 μg/rat, i.c.v.) or H₂ receptor antagonist, ranitidine (60 μg/rat, i.c.v.). However, the neuroleptic effect of haloperidol (0.5 mg/kg, i.p.) was completely reversed by pretreatment with ranitidine (60 μg/rat, i.c.v.), and partially attenuated by chlorpheniramine (80 μg/rat, i.c.v.). These findings suggest the possible involvement of histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol probably via H₁ or H₂ receptor stimulation.
Respiratory deficits in a rat model of Parkinson's disease
2015, Neuroscience
Citation Excerpt :
All behavioral tests were performed on the same day and occurred 1 day before, and 30 and 60 days after vehicle (n = 8), 6 μg (n = 8), 12 μg (n = 8) or 24 μg of 6-OHDA (n = 7). Spontaneous locomotor activity was measured as previously described (Chiavegatto et al., 1998) with minor modifications. The OF apparatus consisted of a white wooden square (100 × 100 × 38 cm) with the floor marked off in 36 squares.
Parkinson’s disease (PD) is a neurodegenerative disease characterized by loss of the dopaminergic nigrostriatal pathway. In addition to deficits in voluntary movement, PD involves a disturbance of breathing regulation. However, the cause and nature of this disturbance are not well understood. Here, we investigated breathing at rest and in response to hypercapnia (7% CO₂) or hypoxia (8% O₂), as well as neuroanatomical changes in brainstem regions essential for breathing, in a 6-hydroxydopamine (6-OHDA) rat model of PD. Bilateral injections of 6-OHDA (24 μg/μl) into the striatum decreased tyrosine hydroxylase (TH⁺)-neurons in the substantia nigra pars compacta (SNpc), transcription factor phox2b-expressing neurons in the retrotrapezoid nucleus and neurokinin-1 receptors in the ventral respiratory column. In 6-OHDA-lesioned rats, respiratory rate was reduced at rest, leading to a reduction in minute ventilation. These animals also showed a reduction in the tachypneic response to hypercapnia, but not to hypoxia challenge. These results suggest that the degeneration of TH⁺ neurons in the SNpc leads to impairment of breathing at rest and in hypercapnic conditions. Our data indicate that respiratory deficits in a 6-OHDA rat model of PD are related to downregulation of neural systems involved in respiratory rhythm generation. The present study suggests a new avenue to better understand the respiratory deficits observed in chronic stages of PD.
The H<inf>3</inf>receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats
2014, European Journal of Pharmacology
Citation Excerpt :
There is a high density of H3 receptors in both striatum and substantia nigra (Cumming et al., 1991; Lovenberg et al., 1999; Pillot et al., 2002a; Ryu et al., 1994, 1996) and there is evidence for alterations in the levels of histamine, the density of histaminergic innervation and the density of H3 receptors in the basal ganglia in PD and 6-OHDA-lesioned rats (Anichtchik et al., 2000, 2001; Nowak et al., 2009; Rinne et al., 2002; Ryu et al., 1994, 1996; Shan et al., 2012). Importantly, histamine and H3 receptors have been implicated in the control of motor activity (Chiavegatto et al., 1998; Nistico et al., 1980; Pillot et al., 2002b; Sakai et al., 1991; Tuomisto and Eriksson, 1980) and they may function to decrease excessive GABA and glutamate release in the basal ganglia thought to underlie dyskinesia (Gomez-Ramirez et al., 2006). In normal rats, H3 agonists can induce ipsilateral rotation when injected unilaterally into the substantia nigra.
The treatment of dyskinesia in Parkinson׳s disease remains poor but H₃ receptor agonists have been suggested as a novel pharmacological approach. We examined the effects of the H₃ agonist, immepip, in 6-OHDA-lesioned rats exhibiting AIMs (abnormal involuntary movements), a rat analogue of dyskinesia, in response to l-dopa compared to the known anti-dyskinetic agents amantadine, MK-801 and 8-OHDPAT. We then attempted to extend these studies in to dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated common marmosets.
Amantadine, MK-801 and 8-OHDPAT all dose-dependently reduced l-dopa-induced axial, lingual and oral (ALO) AIMs in 6-OHDA-lesioned animals accompanied by a reduction in contralateral rotation with higher doses of amantadine and MK-801. By contrast, immepip had no effect on AIMs expression or contralateral rotation. In the MPTP-treated common marmoset exhibiting dyskinesia to l-dopa, immepip alone induced retching and in combination with l-dopa administered subcutaneously or orally induced the rapid onset of retching and vomiting which was not controlled by pretreatment with domperidone. Administration of the unrelated H₃ agonist, imetit had the same effect. Despite causing negative side-effects, it appears that both agonists reduced the antiparkinsonian response to l-dopa resulting in reduced dyskinesia.
H₃ agonists appear unlikely candidates for the treatment of dyskinesia in PD based on lack of evidence of efficacy and potential adverse effects.
Cellular distribution of the histamine H<inf>3</inf> receptor in the basal ganglia: Functional modulation of dopamine and glutamate neurotransmission
2013, Basal Ganglia
Histamine H₃ receptors (H₃R) are widely expressed in the brain where they participate in sleep–wake cycle and cognition among other functions. Despite their high expression in some regions of the basal ganglia, their functional role in this forebrain neural network remains unclear. The present findings provide in situ hybridization and immunohistochemical evidence for H₃R expression in several neuronal populations of the rat basal ganglia but not in astrocytes (glial fibrillary acidic protein immunoreactive cells). We demonstrate the presence of H₃R mRNA and protein in dopaminergic neurons (tyrosine hydroxylase positive) of the ventral tegmental area and substantia nigra. In the dorsal and ventral (nucleus accumbens) striatal complex we show H₃R immunoreactivity in cholinergic (choline acetyltransferase immunoreactive) and GABAergic neurons (substance P, proenkephalin or dopamine D₁ receptor positive) as well as in corticostriatal terminals (VGLUT1-immunoreactive). Double-labelling experiments in the medial prefrontal cortex show that H₃R is expressed in D₁R-positive interneurons and VGLUT1-positive corticostriatal output neurons. Our functional experiments confirm that H₃R ligands modulate dopamine synthesis and the probability of glutamate release in the striatum from cortico-striatal afferents. The presence of H₃R in such different neuronal populations and its involvement in the control of striatal dopaminergic and glutamatergic transmission ascribes a complex role to H₃R in the function of the basal ganglia neural network.

View all citing articles on Scopus

View full text

Histamine and spontaneous motor activity: Biphasic changes, receptors involved and participation of the striatal dopamine system

Abstract

Progr. Neurobiol.

Neurosci. Lett.

Physiol. Behav.

Physiol. Behav.

Physiol. Behav.

Neuroscience

Neuroscience

Life Sci.

Life Sci.

Behav. Brain Res.

Brain Res.

Brain Res.

Eur. J. Pharmacol.

Brain Res. Rev.

Eur. J. Pharmacol.

Eur. J. Pharmacol.

Eur. J. Pharmacol.

Eur. J. Pharmacol.

Physiol. Rev.

J. Pharmacol. Exp. Ther.

Res. Commun. Chem. Pathol. Pharmacol.

Agents Actions

Arch. Int. Pharmacodyn. Ther.